197094-19-2

Basic information

• Product Name: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one
• Synonyms: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one;6,7-dihydro-5H-pyrazolo[1,5-a]pyridin-4-one
• CAS NO: 197094-19-2
• Molecular Formula: C7H8N2O
• Molecular Weight: 136.15122
• Mol File: 197094-19-2.mol

Chemical Properties

• Boiling Point: 281.8±9.0 °C(Predicted)
• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.18±0.20(Predicted)
• CAS DataBase Reference: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one(197094-19-2)
• EPA Substance Registry System: 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one(197094-19-2)

Safety Data

• Hazardous Substances Data: 197094-19-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one is used as a potential active pharmaceutical ingredient for the development of anti-inflammatory and analgesic medications. Its unique structure and properties make it a candidate for creating new drugs that could offer effective treatment options for various conditions characterized by inflammation and pain.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one serves as a valuable compound for research and development. Scientists and researchers utilize its chemical structure to explore new drug design strategies, potentially leading to the creation of innovative therapeutic agents with improved efficacy and reduced side effects.
While the provided materials do not specify other industries or applications for 6,7-Dihydropyrazolo[1,5-a]pyridin-4(5H)-one, its primary focus is on its potential within the pharmaceutical and medicinal chemistry sectors. Further research may reveal additional applications in various industries, depending on the compound's properties and the outcomes of ongoing studies.

Upstream product

• 110525-56-9 4-(1H-pyrazol-1-yl)butanoic acid 
• 110525-55-8 4-Pyrazol-1-yl-butyric acid ethyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors

We report herein the synthesis of novel ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors and the evaluation of pharmaceutical activity against five cancer cell lines (MDA-MB-231, BXPC-3, NCI-H1975, DU145 and 786O). Generally, the majority of compounds displayed strong anti-FAK enzymatic potencies (IC50 1 nM) and could effectively inhibit several class of cancer cell lines within the concentration of 3 μM in comparison with GSK2256098 as a reference. Among them, compound 4o is considered to be the most effective due to high sensitivity in antiproliferation. In culture, 4o could not only inhibit FAK Y397 phosphorylation in MDA-MB-231 cell line, but also trigger apoptosis in a dose-dependent manner. Furthermore, computational docking analysis also suggested that 4o and TAE-226 displayed the similar interaction with FAK kinase domain.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Chemical Compounds

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

Novel Parham-type Cycloacylations of 1H-Pyrazole-1-alkanoic Acids

Exposure of 1H-pyrazole-1-alkanoic acids to two equivalents of n-butyllithium affords the corresponding cyclic ketones via a Parham-type cyclization process. Although yields are modest, this procedure represents a simple and direct intramolecular acylation of a non-nucleophilic pyrazole carbon.